Annual report pursuant to Section 13 and 15(d)

Acquisition (Details)

v3.3.1.900
Acquisition (Details)
$ / shares in Units, sample in Thousands, $ in Thousands
 12 Months Ended
Oct. 31, 2014
USD ($)
installment
$ / shares
shares
Aug. 13, 2014
USD ($)
sample
Dec. 31, 2015
USD ($)
$ / shares
Dec. 31, 2014
USD ($)
$ / shares
Dec. 22, 2015
USD ($)
Aug. 31, 2013
USD ($)
Business Acquisition [Line Items]            
Cash paid to acquire business     $ 0 $ 13,359    
Finite-lived intangible assets, gross     47,468 47,468    
Contingent consideration - deferred payments     $ 18,549 $ 26,542   $ 500
Common stock, par value (usd per share) | $ / shares     $ 0.01 $ 0.01    
Exit Fee     $ 1,400      
Goodwill     0 $ 15,545    
FDIC indemnification asset, acquisitions $ 2,500          
Interpace Diagnostics, LLC            
Business Acquisition [Line Items]            
Assets acquired, samples | sample   5        
Cash paid to acquire business   $ 8,000        
Transition services obligation   500        
Other Commitment   500        
Finite-lived intangible assets, gross   $ 13,000        
Finite-lived intangible asset, useful life   7 years 10 months 24 days        
Contingent consideration - deferred payments   $ 4,476        
Total consideration   $ 12,976        
RedPath Integrated Pathology, Inc            
Business Acquisition [Line Items]            
Cash paid to acquire business 13,400          
Transition services obligation 22,066          
Contingent consideration - deferred payments 23,886          
Working capital adjustment 1,600   0 1,820    
Contingent cash payments on annual net sales 5,000          
Goodwill 15,666          
Total consideration 44,975          
RedPath            
Business Acquisition [Line Items]            
Contingent consideration - deferred payments     13,921 22,066    
Working capital adjustment       1,800    
Diagnostic Test - Pancreas | Interpace Diagnostics, LLC            
Business Acquisition [Line Items]            
Royalty Percentage   5.00%        
Royalty Percentage Period   10 years        
Total consideration   $ 2,882        
Diagnostic Test - Thyroid | Interpace Diagnostics, LLC            
Business Acquisition [Line Items]            
Royalty Percentage   3.50%        
Total consideration   $ 8,519        
Diagnostic Test- Other Thyroid | Interpace Diagnostics, LLC            
Business Acquisition [Line Items]            
Royalty Percentage   1.50%        
Royalty Percentage Period   10 years        
Barrett's Esophagus | RedPath Integrated Pathology, Inc            
Business Acquisition [Line Items]            
Annual net sales threshold 14,000          
Interpace and RedPath | RedPath Integrated Pathology, Inc            
Business Acquisition [Line Items]            
Annual net sales threshold $ 37,000          
Biobank | Interpace Diagnostics, LLC            
Business Acquisition [Line Items]            
Total consideration   $ 1,575        
Notes Payable, Other Payables            
Business Acquisition [Line Items]            
Long-term debt     8,400      
Notes Payable, Other Payables | RedPath Integrated Pathology, Inc            
Business Acquisition [Line Items]            
Number of equal consecutive quarterly installments | installment 8          
Stated interest rate 5.00%          
Long-term debt     $ 7,300      
Debt discount rate     13.50%      
Equity interests issued | shares 500,000          
Common stock, par value (usd per share) | $ / shares $ 0.01          
Face amount $ 11,000          
Loans | RedPath Integrated Pathology, Inc            
Business Acquisition [Line Items]            
Long-term debt     $ 18,800      
Face amount 20,000       $ 20,000  
Proceeds from issuance of debt 19,600          
Loan Processing Fee 300          
Exit Fee 800          
PathFinderTG | RedPath Integrated Pathology, Inc            
Business Acquisition [Line Items]            
Royalty Percentage   10.00%        
Annual net sales threshold 30,000          
Barrett's Esophagus | RedPath Integrated Pathology, Inc            
Business Acquisition [Line Items]            
Royalty Percentage   20.00%        
Annual net sales threshold 30,000          
PathFinderTG-Pancreas | RedPath Integrated Pathology, Inc            
Business Acquisition [Line Items]            
Royalty Percentage   6.50%        
Annual net sales threshold $ 12,000          
RedPath            
Business Acquisition [Line Items]            
Finite-lived intangible assets, gross   $ 34,500        
Finite-lived intangible asset, useful life   8 years 22 days        
Goodwill     0 15,545    
Reported Value Measurement [Member]            
Business Acquisition [Line Items]            
Contingent consideration - deferred payments     18,549 26,542    
Reported Value Measurement [Member] | RedPath            
Business Acquisition [Line Items]            
Contingent consideration - deferred payments     $ 13,921 $ 22,066